Cargando…
Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
The increased cardiovascular risk of chronic kidney disease may in part be the consequence of arterial stiffness, a typical feature of kidney failure. Deranged homeostasis of minerals and hormones involved (CKD-MBD), are also strongly associated with this increased risk. It is well established that...
Autor principal: | Vervloet, Marc G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616505/ https://www.ncbi.nlm.nih.gov/pubmed/37915898 http://dx.doi.org/10.1093/ckj/sfad112 |
Ejemplares similares
-
Management of fracture risk in CKD—traditional and novel approaches
por: Haarhaus, Mathias, et al.
Publicado: (2022) -
Unmet needs in clinical trials in CKD: questions we have not answered and answers we have not questioned
por: Levin, Adeera, et al.
Publicado: (2022) -
Leukocyte–endothelial interaction in CKD
por: Sarakpi, Tamim, et al.
Publicado: (2023) -
Thiazide diuretics are back in CKD: the case of chlorthalidone
por: Minutolo, Roberto, et al.
Publicado: (2022) -
Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?
por: Leoncini, Giovanna, et al.
Publicado: (2022)